
FTAI Aviation: Innovation Is Their DNA
Track DNA's AI-powered predictions, market trends, and investment insights.
StockTwits Mentions
0
DNA has been mentioned an estimated 0 times on StockTwits over the last 24 hours.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedGinkgo Bioworks Holdings is currently unprofitable, as indicated by its negative EPS and PE ratio. The magnitude of the loss per share suggests that the company is still in a heavy investment or early commercialization phase, with profitability likely some distance away. Without evidence of rapidly improving margins or a clear path to positive earnings, the financial profile remains high-risk.
The stock trades at $8.00, modestly up 3.8% over the last month, but remains below its 200-day moving average of $9.47, indicating a longer-term downtrend or at least technical weakness. The negative PE ratio reflects ongoing losses, and the price recovery so far is not strong enough to signal a clear reversal in trend. Overall, technicals lean cautious to bearish until the stock can sustainably trade above its long-term moving average.
Alternative data for Ginkgo Bioworks is mixed but slightly constructive: hiring is up and most social channels are growing, which signals ongoing operational activity and brand visibility. However, overall web traffic remains modest and social media growth is relatively slow, suggesting limited near-term inflection in customer or investor engagement. These signals support a stable to cautiously improving outlook, but not a strong growth acceleration story by themselves.
Overall, Ginkgo Bioworks Holdings appears fundamentally and technically challenged, with significant ongoing losses and a share price still below its long-term moving average. While alternative data such as modest hiring growth and slowly rising social followership suggest the business is active and incrementally building its presence, these positives do not yet offset the risks associated with persistent unprofitability. On balance, the current setup leans bearish, with the stock more suitable for investors comfortable with high risk and a long time horizon.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
You don't hold DNA in your mock portfolio yet.

FTAI Aviation: Innovation Is Their DNA



DNA X, Inc. Reports First Quarter 2026 Financial Results
Ginkgo Bioworks (DNA) generated 92 StockTwits mentions over the past seven days, reflecting a moderate but consistent level of retail trader attention for a small-cap biotech priced at $7.89. That level of social activity suggests the stock remains on active watchlists despite a 1.4% single-day price decline. DNA StockTwits conversations tend to cluster around its long-term biotech narrative and speculative positioning, with traders monitoring for any catalysts that could shift momentum in either direction.
With a market cap of just $515.4 million and daily volume of 695,750 shares, DNA sits in a space where social sentiment can carry meaningful weight. The 92 StockTwits mentions over seven days, combined with only 7 Reddit mentions, suggest attention is concentrated on short-form trading platforms rather than deeper research communities. The stock's AI score of 5/10 signals a neutral outlook — neither a strong buy nor a clear avoid — which aligns with a social sentiment picture that appears cautious rather than euphoric or capitulatory.
TrendEdge aggregates DNA StockTwits data alongside Reddit mention volume, proprietary AI scoring, price action, and trading volume to give traders a multi-dimensional view of market sentiment. Rather than relying on any single signal, TrendEdge cross-references social chatter with quantitative indicators to surface whether community buzz is aligned with or diverging from fundamental and technical momentum — helping traders cut through noise and act on higher-confidence insights.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
8,910
Twitter Followers
39,798
Instagram Followers
13,074
LinkedIn Followers
109,585
Job Postings
12
LinkedIn Employees
539
News Mentions
0
Key Metrics